Sarepta Therapeutics Future Growth
Future criteria checks 5/6
Sarepta Therapeutics is forecast to grow earnings and revenue by 42.6% and 19.5% per annum respectively. EPS is expected to grow by 42.9% per annum. Return on equity is forecast to be 48.4% in 3 years.
Key information
42.6%
Earnings growth rate
42.9%
EPS growth rate
Biotechs earnings growth | 23.6% |
Revenue growth rate | 19.5% |
Future return on equity | 48.4% |
Analyst coverage | Good |
Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,293 | 1,065 | N/A | 1,064 | 11 |
12/31/2025 | 2,898 | 1,004 | 505 | 717 | 18 |
12/31/2024 | 1,852 | 214 | 729 | 146 | 18 |
12/31/2023 | 1,243 | -536 | -486 | -501 | N/A |
9/30/2023 | 1,105 | -691 | -512 | -539 | N/A |
6/30/2023 | 1,003 | -908 | -431 | -489 | N/A |
3/31/2023 | 976 | -1,115 | -468 | -434 | N/A |
12/31/2022 | 933 | -703 | -358 | -325 | N/A |
9/30/2022 | 876 | -716 | -289 | -262 | N/A |
6/30/2022 | 835 | -507 | -348 | -322 | N/A |
3/31/2022 | 766 | -357 | -285 | -364 | N/A |
12/31/2021 | 702 | -419 | -382 | -443 | N/A |
9/30/2021 | 646 | -486 | -551 | -588 | N/A |
6/30/2021 | 600 | -634 | -681 | -702 | N/A |
3/31/2021 | 573 | -704 | -795 | -701 | N/A |
12/31/2020 | 540 | -554 | 133 | 107 | N/A |
9/30/2020 | 495 | -601 | 155 | 118 | N/A |
6/30/2020 | 450 | -530 | 342 | 289 | N/A |
3/31/2020 | 407 | -656 | 373 | 318 | N/A |
12/31/2019 | 381 | -715 | -516 | -456 | N/A |
9/30/2019 | 365 | -620 | -478 | -415 | N/A |
6/30/2019 | 345 | -570 | -536 | -461 | N/A |
3/31/2019 | 323 | -403 | -567 | -499 | N/A |
12/31/2018 | 301 | -362 | -450 | -389 | N/A |
9/30/2018 | 274 | -245 | -345 | -297 | N/A |
6/30/2018 | 241 | -216 | -277 | -242 | N/A |
3/31/2018 | 203 | -170 | -238 | -210 | N/A |
12/31/2017 | 155 | -51 | -128 | -232 | N/A |
9/30/2017 | 103 | -115 | N/A | -282 | N/A |
6/30/2017 | 57 | -124 | N/A | -285 | N/A |
3/31/2017 | 22 | -123 | N/A | -243 | N/A |
12/31/2016 | 5 | -267 | N/A | -246 | N/A |
9/30/2016 | 1 | -243 | N/A | -196 | N/A |
6/30/2016 | 1 | -239 | N/A | -182 | N/A |
3/31/2016 | 1 | -218 | N/A | -167 | N/A |
12/31/2015 | 1 | -220 | N/A | -149 | N/A |
9/30/2015 | 0 | -200 | N/A | -144 | N/A |
6/30/2015 | 1 | -177 | N/A | -133 | N/A |
3/31/2015 | 4 | -169 | N/A | -144 | N/A |
12/31/2014 | 10 | -136 | N/A | -129 | N/A |
9/30/2014 | 12 | -100 | N/A | -121 | N/A |
6/30/2014 | 15 | -113 | N/A | -105 | N/A |
3/31/2014 | 16 | -98 | N/A | -78 | N/A |
12/31/2013 | 14 | -112 | N/A | -65 | N/A |
9/30/2013 | 19 | -165 | N/A | -54 | N/A |
6/30/2013 | 22 | -173 | N/A | -42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: S1RP34 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (9.8%).
Earnings vs Market: S1RP34 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: S1RP34 is expected to become profitable in the next 3 years.
Revenue vs Market: S1RP34's revenue (19.5% per year) is forecast to grow faster than the BR market (7.2% per year).
High Growth Revenue: S1RP34's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: S1RP34's Return on Equity is forecast to be very high in 3 years time (48.4%).